Neurotech secures $3.15 million R&D tax incentive loan
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Neurotech International Ltd. has announced a secured loan agreement for research and development funding. The loan, amounting to a significant sum, is secured against anticipated refundable tax incentives for upcoming financial years. Proceeds from the loan will support Phase III Clinical Studies in Autism Spectrum Disorder and other ongoing research activities. This announcement was authorized by the Board of Neurotech International Limited.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- US FDA clears IND for NTI164
- NTI secures Notices of Allowance for US patent applications
- NTI initiates First Clinical Site for Phase 3 ASD Trial
- Appendix 4D & Half Year Report
- Positive 90-day GLP toxicology study results in non-rodents
Later from Neurotech International
- NTI164 Phase II/III Autism Data Accepted for Publication
- Trading Halt
- Quarterly Activities/Appendix 4C Cash Flow Report
- Proposed issue of securities - NTI
- Receipt of Binding Commitments for $4.5m Placement
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International